¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"neutrophilic leukaemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neutrophilic granule
    È£Áß¼º°ú¸³
  • neutrophilic leukemoid reaction
    Áß¼º±¸¹éÇ÷º´¸ð¾ç¹ÝÀÀ, È£Áß±¸¹éÇ÷º´¸ð¾ç¹ÝÀÀ
  • neutrophilic myelocyte
    Áß¼º±¸°ñ¼ö¼¼Æ÷, È£Áß¼º°ñ¼ö¼¼Æ÷
  • neutrophilic promyelocyte
    È£Áß¼ºÀü°ñ¼ö¼¼Æ÷, È£Áß¼ºÇ²»À¼ÓÁú¼¼Æ÷
  • segmented neutrophilic leukocyte
    ºÐ¿±ÇÙÈ£Áß¹éÇ÷±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rheumatoid neutrophilic dermatitis
    ·ù¸¶Æ¼½ºÈ£Áß±¸ÇǺο°
  • neutrophilic granule
    È£Áß¼º°ú¸³
  • neutrophilic eccrine hidradenitis
    È£Áß±¸¿¡Å©¸°¶¡»ù¿°
  • segmented neutrophilic leukocyte
    ºÐ¿±ÇÙÈ£Áß¼º¹éÇ÷±¸
  • neutrophilic metamyelocyte
    È£Áß¼º´Ê°ñ¼ö¼¼Æ÷
  • neutrophilic myelocyte
    È£Áß¼º°ñ¼ö¼¼Æ÷
  • neutrophilic promyelocyte
    È£Áß¼ºÇ²°ñ¼ö¼¼Æ÷
  • neutrophilic leukemoid reaction
    È£Áß±¸¹éÇ÷º´¸ð¾ç¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute febrile neutrophilic dermatosis ; Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ.
  • acute febrile neutrophilic dermatosis = Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neutrophilic metamyelocyte [juvenile neutrophilic leukocyte]
    È£Áß¼º´Ê°ñ¼ö¼¼Æ÷ (¾î¸°È£Áß¼º¹é
  • acute megakaryoblastic leukaemia
    ±Þ¼º°Å´ë¸ð±¸¼º¹éÇ÷º´
  • leukemia =leukaemia
    ¹éÇ÷º´.
  • leukemia =leukaemia
    ¹éÇ÷º´
  • acute febrile neutrophilic dermatosis ; Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ.
  • acute febrile neutrophilic dermatosis = Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ
  • intra-epidermal neutrophilic IgA dermatosis
    Ç¥Çdz»È£Áß±¸¼º ¸é¿ª±Û·ÎºÒ¸°A ÇǺκ´
  • juvenile neutrophilic leukocyte
    ¾î¸°È£Áß¼º¹éÇ÷±¸
  • neutrophilic
    È£Áß¼º(Ì´Ì¡ËÛ)ÀÇ, Áß¼ºÄ£È­¼º(Ì¡ËÛ̴̬ËÛ)ÀÇ.
  • neutrophilic
    È£Áß¼ºÀÇ, Áß¼ºÄ£È­¼ºÀÇ
  • neutrophilic granulocyte
    È£Áß±¸¼º ¹éÇ÷±¸
  • neutrophilic eccrine hidradenitis
    È£Áß±¸¼º ¿¡Å©¸° ÇѼ±¿°
  • neutrophilic granule
    È£Áß¼º°ú¸³
  • neutrophilic granulocyte
    È£Áß±¸¼º °ú¸³±¸
  • neutrophilic leukemia
    È£Áß±¸¼º ¹éÇ÷º´
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Neutrophilic metamyelocyte [Juvenile neutrophilic leukocyte]
    È£Áß¼º´Ê°ñ¼ö¼¼Æ÷ [¾î¸°È£Áß¼º¹éÇ÷±¸]
    [¿¾ ¿ë¾î] Áß¼ºÈ£¼ºÈİñ¼ö¼¼Æ÷
  • Neutrophilic granule
    È£Áß¼º°ú¸³
    [¿¾ ¿ë¾î] Áß¼ºÈ£¼º°ú¸³
  • Segmented neutrophilic leukocyte
    ºÐ¿±ÇÙÈ£Áß¼º¹éÇ÷±¸
    [¿¾ ¿ë¾î] ºÐ¿±Áß¼ºÈ£¼º¹éÇ÷±¸
  • Juvenile neutrophilic leukocyte
    ¾î¸°È£Áß¼º¹éÇ÷±¸
    [¿¾ ¿ë¾î] Áß¼ºÈ£¼ºÈİñ¼ö¼¼Æ÷
  • Neutrophilic myelocyte
    È£Áß¼º°ñ¼ö¼¼Æ÷
    [¿¾ ¿ë¾î] Áß¼ºÈ£¼º°ñ¼ö¼¼Æ÷
  • Neutrophilic leukocyte
    È£Áß¼º¹éÇ÷±¸
    [¿¾ ¿ë¾î] Áß¼ºÈ£¼º¹éÇ÷±¸
  • Neutrophilic promyelocyte
    È£Áß¼ºÇ²°ñ¼ö¼¼Æ÷
    [¿¾ ¿ë¾î] Áß¼ºÈ£¼ºÀü°ñ¼ö¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NCF Neutrophilic Chemotatic Factors
PMNL Poly-Morpho-Nuclear neutrophilic Leukocyte
AFND acute febrile neutrophilic dermatosis
C-ANCA cytoplasmic anti-neutrophilic cytoplasmic antibody
CNL cardiolipin natural lecithin; chronic neutrophilic leukemia
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CNL Chronic neutrophilic leukaemia
NEH Neutrophilic eccrine hidradenitis
PMN Polymorphonuclear neutrophilic granulocytes
PMN Polymorphonuclear neutrophilic leukocytes
A-MuL V Abelson murine leukaemia virus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute febrile neutrophilic dermatosis
    ±Þ¼º ¹ß¿­¼º È£Áß±¸¼º ÇǺο°
  • neutrophilic leukocyte
    È£Áß¼º ¹éÇ÷±¸
  • neutrophilic myelocyte
    È£Áß °ñ¼ö±¸, È£Áß¼º °ñ¼ö±¸, Áß¼º ģȭ °ñ¼ö±¸, Áß¼º ģȭ¼º °ñ¼ö±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
neutrophilic leukaemia An unusual form of chronic granulocytic leukaemia in which the greatly increased number of leukocytes in the circulating blood are mature polymorphonuclear neutrophils, with virtually no young or immature granulocytes being observed.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acute febrile neutrophilic dermatosis A rare dermatosis, predominant in women, of rapid onset and characterised by plaque-like lesions, usually multiple, on the face, neck, and upper extremities, accompanied by conjunctivitis, mucosal lesions, fever, malaise, arthralgia, and peripheral blood neutrophilia in many cases; biopsy reveals polymorphonuclear infiltrate of the dermis; rapid remission occurs with systemic steroid therapy.
Synonym: Sweet's disease.
(05 Mar 2000)
neutrophilic 1. Pertaining to or characterised by neutrophils, such as an exudate in which the predominant cells are neutrophilic granulocytes.
2. Characterised by a lack of affinity for acid or basic dyes, i.e., staining approximately equally with either type.
Synonym: neutrophilous.
(05 Mar 2000)
neutrophilic leukocyte A neutrophilic granulocyte, the most frequent of the polymorphonuclear leukocyte's, and also the most active phagocyte among the various types of white blood cells; when treated with Wright's stain (or similar preparations), the fairly abundant cytoplasm is faintly pink, and numerous tiny, slightly refractile, relatively bright pink or violet-pink, diffusely scattered granules are recognizable in the cytoplasm; the deeply stained blue or purple-blue nucleus is sharply distinguished from the cytoplasm and is distinctly lobated, with thin strands of chromatin connecting the three to five lobes.
(05 Mar 2000)
neutrophilic leukocytosis Too many neutrophils.
(12 Dec 1998)
neutrophilic leukopenia <haematology> Leucopenia in which the decrease in white blood cells is chiefly in neutrophils.
(18 Nov 1997)
abelson leukaemia virus A defective murine leukaemia virus capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukaemia after superinfection with friend, moloney, or rauscher virus.
(12 Dec 1998)
Abelson murine leukaemia virus A retrovirus belonging to the Type C retrovirus group subfamily (family Oncovirinae) which is associated with leukaemia and produces in vitro transformation of mouse cells.
(05 Mar 2000)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acute granulocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
Origin: Gr. Haima = blood
(27 Sep 1997)
acute leukaemia <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months.
See: acute lymphoblastic leukaemia, acute myeloid leukaemia.
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphoblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting the type of white blood cell known as lymphocytes. Approximately 650 new cases are diagnosed every year in the UK and it is the most common form of childhood leukaemia.
Acronym: ALL
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphocytic leukaemia <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis
(12 Dec 1998)
acute monocytic leukaemia <haematology> The most common translocation in this disorder of poorly differentiated monocytic cells involves chromosome region 11q in a large percentage of cases.
The translocation involves a cellular oncogene, c-ets which is mapped to the 11q23-24 region. The most common translocations reported are t(6;11), t(9;11), t(11;17) and t(11;19), of which t(9;11) (p21-22;q23) is by far the most frequently detected and implicated in acute myeloid leukaemia. The cells express CD14 surface antigen, which is diagnostic of monocytic cells.
Acronym: AML
Classification: FAB M5
(07 Apr 1998)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukaemia
    ¹éÇ÷º´
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á